(Total Views: 613)
Posted On: 04/15/2020 8:13:06 PM
Post# of 155038
I believe that Actemra (Genentech) just started clinical trials. It is Kevzara (Regeneron) the other IL-6 inihibtor that started trials in mid March.
There is a new immunomodulator, baracitinib by Lilly that just joined the race. This might be more broad acting in cytokine storm and maybe more of a competitor than the other 2 IMO.
Patterson seems to mention his feelings on the limitation of just inhibiting IL6 in the ProActiv videos. He basically says there is more to cytokine storm than just IL6, ie TNF and other cytokines are also involved. He also says IL6 inihibition does not address the CD8 deficiency in these patients which is needed to fight the virus and other opportunistic infections.
I don't know much more than this and will defer to others.
There is a new immunomodulator, baracitinib by Lilly that just joined the race. This might be more broad acting in cytokine storm and maybe more of a competitor than the other 2 IMO.
Patterson seems to mention his feelings on the limitation of just inhibiting IL6 in the ProActiv videos. He basically says there is more to cytokine storm than just IL6, ie TNF and other cytokines are also involved. He also says IL6 inihibition does not address the CD8 deficiency in these patients which is needed to fight the virus and other opportunistic infections.
I don't know much more than this and will defer to others.
(4)
(0)
